Damora Therapeutics
(NASDAQ) DMRA
Damora Therapeutics Financials at a Glance
Market Cap
$1.31B
Revenue (TTM)
$0.00
Net Income (TTM)
-$235.09M
EPS (TTM)
-$126.87
P/E Ratio
-0.17
Dividend
$0.00
Beta (Volatility)
1.55 (High)
Dividend
$0.00
Beta (Volatility)
1.55 (High)
Price
$24.79
Volume
159,106.551
Open
$21.51
Price
$24.79
Volume
159,106.551
Open
$21.51
Previous Close
$21.23
Daily Range
$21.51 - $24.79
52-Week Range
$2.45 - $38.33
Estimated Earnings Date
Aug 5, 2026
Dividend
$0.00
Beta (Volatility)
1.55 (High)
Price
$24.79
Volume
159,106.551
Open
$21.51
Previous Close
$21.23
Daily Range
$21.51 - $24.79
52-Week Range
$2.45 - $38.33
Estimated Earnings Date
Aug 5, 2026
DMRA News
DMRA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Damora Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
7
CEO
Sherwin Sattarzadeh, MBA
Website
www.galecto.comHeadquarters
Waltham, MA 02109, US
DMRA Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-90%
Return on Capital
-47%
Return on Assets
-44%
Earnings Yield
-5.88%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.31B
Shares Outstanding
61.57M
Volume
159.11K
Avg. Volume
350.82K
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$210.87M
EBITDA
-$209.76M
Operating Cash Flow
-$6.73M
Capital Expenditure
$0.00
Free Cash Flow
-$6.73M
Cash & ST Invst.
$257.62M
Total Debt
$68.00K
Damora Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$68.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$1.31B
N/A
Market Cap/Employee
$186.74M
N/A
Employees
7
N/A
Net Income
-$27.78M
-996.8%
EBITDA
-$27.67M
-996.8%
Quarterly Fundamentals
Total Cash
$532.90M
+4363.5%
Total Debt
$1.34M
-6.4%
Accounts Receivable
$894.00K
-2.5%
Inventory
$0.00
N/A
Long Term Debt
$1.34M
-5.6%
Short Term Debt
$0.00
-100.0%
Return on Assets
-43.91%
N/A
Return on Invested Capital
-46.73%
N/A
Free Cash Flow
-$20.60M
-79.5%
Operating Cash Flow
-$20.60M
-79.5%